Kornimate/medical-research-clean huggingface dataset:
mindfulness training in military spouses

Conditions: Psychological Stress

Summary: this project aims to contextualize the delivery of mindfulness training for military spouses and evaluate its effectiveness on measures of executive functions and psychological well-being.

in addition to psychological and physical health challenges that military service members face, military deployment is known to have deleterious effects on the entire family unit. the january 2010 issue of the new england journal of medicine reported medical data from over 250,000 wives of deployed soldiers. these women suffered from clinically significant levels of anxiety, depression, sleep disturbances, and adjustment disorders. thus, the psychological profile of military spouses sadly parallels that of the military servicemembers. unfortunately, the effect of deployment on the psychological health in military spouses is largely unstudied, and very few resilience-building programs are available for military families. prior research showed that mindfulness training (mt), as a resilience-building program in civilian and military servicemembers, can effectively protect against degradation in of executive functions (i.e., attention, working memory) and benefit psychological well-being over high-demand intervals. while research evidence mounts that mt is beneficial for service members, there is almost no research examining the impact of mt on military spouses' cognitive functioning and psychological well-being. the present study aims to investigate if mt may successfully benefit cognitive functioning and psychological well-being in military spouses.

Eligibility criteria:
inclusion criteria: * english-speaking * being in a relationship or married to u.s. army active-duty member or veteran. exclusion criteria: * a non-controlled severe medical disease that might interfere with the performance in the study. * any other condition that the investigator might deem problematic for the inclusion of the volunteer in a training study of this nature.
ezetimibe-ursodiol combination therapy on biomarkers of liver function and sterol balance in subjects with nafld

Conditions: Nonalcoholic Fatty Liver Disease (NAFLD)

Summary: the purpose of this research is to gather information on the combination zetia® (ezetimibe) and urso forte® with respect to sterol balance and their effects on biomarkers of liver function in subjects with nonalcoholic fatty liver disease (nafld).

the study will be conducted as a prospective open label trial with pre- and post-treatment measures for all dependent variables. this trial will enroll subjects with a clinical diagnosis of nonalcoholic fatty liver disease (nafld) by magnetic resonance imaging (mri), computed tomography (ct) or ultrasound, including those diagnosed with nonalcoholic steatohepatitis (nash). subjects will be consented, blood collected and a mri conducted on the first visit. patients will be advised on the proper use of the study drug and given the first three month's supply of the study drug to take home with them. for the remaining three months, study drug will be delivered by us mail along with return packaging for the prior three month's study medication in order to monitor compliance. patients will be called routinely to encourage compliance, retention, and monitor side effects or adverse events. after six months of study drug administration, subjects will return for a follow-up visit. blood will be drawn, an mri will be obtained and a post-study questionnaire will be administered. duration of patient enrollment: 6 months duration of study: 18 months

Eligibility criteria:
inclusion criteria: * steatosis * alt \>1.5 times normal * alt/ast ratio \>1.0 * normal kidney function exclusion criteria: * normal alt within last 6 months * advanced fibrosis based on 1) biopsy, if available (stage 3 or 4 nafld), 2) imaging, or 3) lab (platelet count \<150,000) * daily alcohol use above 20 g/day for women and 30 g/day for men * prescription use of ursodiol, ezetimibe, vitamin e, fish oils, thiazolidinediones, insulin, sulfonylureas, hmg-coa reductase inhibitors * weight loss greater than 15% in past 12 months * pregnant or breastfeeding * body mass index greater than 50 * largest body circumference greater than 160 cm * claustrophobia * allergy to ezetimibe or ursodiol

Keywords: nonalcoholic fatty liver disease nafld
implementing a nurse-driven aromatherapy protocol to decrease the effect of postoperative nausea and vomiting

Conditions: Postoperative Nausea and Vomiting (PONV)

Summary: this is a quality improvement project that aims to assess the effect of nurse-driven administration of essential oil aromatherapy on postoperative nausea and vomiting (ponv) in patients while in the post-anesthesia care unit (pacu) after general anesthesia.

in this three-month quality improvement project, nurse-driven aromatherapy will be offered to all patients in the main pacu setting at the hospital corporation of america (hca) houston healthcare southeast hospital after they have undergone surgical procedures with general anesthesia, with the exception of patients who report allergies or sensitivity to ginger or lavender essential oils (eo) and patients who wish to be excluded from the project.

Eligibility criteria:
inclusion criteria: * pacu patients who are in the main pacu setting at hca houston healthcare southeast hospital after having undergone general anesthesia for a surgical procedure exclusion criteria: * patients with allergies or sensitivity to ginger or lavender essential oils * patients who wish to be excluded from the project

Keywords: aromatherapy
efficacy study measuring the impact of pregabalin on peripheral neuropathic pain.

Conditions: Neuropathic Pain

Summary: this study will measure the impact of treatment with pregabalin in adult men and women who have a diagnosis of peripheral neuropathic pain (pain caused by a primary lesion of the peripheral nervous system such as diabetic peripheral neuropathy and postherpetic neuralgia).


Eligibility criteria:
inclusion criteria: * subjects presenting a diagnosis of peripheral neuropathic pain, defined as pain caused by a lesion of the peripheral nervous system manifesting with sensory symptoms and signs, for at least 6 months at screening. * at baseline, subjects must have completed at least 4 daily pain diaries and must have a mean weekly pain score equal or greater than 4. exclusion criteria: * presence of any of the following diagnoses: cervical or lumbo-sacral radiculopathy; operated or non-operated chronic low back pain carpal tunnel syndrome or any other entrapment-related neuropathic pain (defined as pain associated with focal nerve lesion produced by constriction or mechanical distortion of the nerve, within a fibrous or fibro-osseous tunnel, or by a fibrous band) ; complex regional pain syndrome (type 1 and 2); fibromyalgia.
a trial of 18f-av-133 and 18f-av-45 positron emission tomography (pet)

Conditions: Dementia With Lewy Bodies; Alzheimer's Disease; Parkinson's Disease

Summary: the purpose of this study is to evaluate the ability to identify individuals with dopaminergic degeneration in group of patients with a clinical diagnosis of either dementia with lewy bodies (dlb) or idiopathic parkinson's disease and to differentiate them from alzheimer's disease (ad) and control subjects.


Eligibility criteria:
inclusion criteria dlb: * male or female \> 50 years of age * meet the diagnostic criteria for probable dlb as established by the dlb consortium (mckeith et al., 2005) inclusion criteria ad: * male or female \> 50 years of age * meet the nincds criteria for probable ad and have a mini mental state examination (mmse) score at screening between 10 and 24 inclusive inclusion criteria pd: * male or female \> 50 years of age * have probable pd according to the following criteria (gelb et al., 1999): * presence of 2 of the following 3 features: rest tremor, rigidity, bradykinesia; * documented history of a sustained (\>6 months) improvement to levodopa (l-dopa) or a dopamine agonist * absence of atypical clinical features or other possible signs or symptoms suggesting another cause of parkinsonism such as a history of frequent falls as a prominent early feature, localized brain lesion(s) or neuroleptic use * asymmetric onset * a diagnosis of pd made within the 4 years prior to enrollment normal subjects: * are males or females \> 50 years of age * have a mmse score \> 29, and are cognitively normal on the psychometric test battery at screening * have no signs or symptoms of clinically meaningful parkinsonism exclusion criteria: * have a history or current diagnosis of other neurologic disease * have evidence of clinically significant cerebrovascular disease * have evidence from mri or other biomarker studies that suggests the presence of a cns pathology other than that associated with the study diseases
combined intrathecal dexmedetomidine and adductor canal block for analgesia after total knee arthroplasty

Conditions: Intrathecal Dexmedetomidine; Adductor Canal Block; Analgesia; Total Knee Arthroplasty

Summary: the aim of this work is to evaluate the effect of combined intrathecal dexmedetomidine and adductor canal block for analgesia after total knee arthroplasty (tka).

effective postoperative pain management is essential for improving patient outcomes following knee surgery, facilitating early mobilization, and reducing the risk of complications. the adductor canal block (acb) is a nerve block of hunters canal, which includes the saphenous and vastus medialis nerves. additionally, other sensory nerves, such as the femoral nerve, medial cutaneous nerve, and both the anterior branch and terminal end of the posterior branch of the obturator nerve to some extent as it enters the distal part of the canal are blocked by the acb. dexmedetomidine (dxm) a highly selective α2 adrenergic agonist with sedative, anxiolytic, analgesic, sympatholytic and antihypertensive effects.

Eligibility criteria:
inclusion criteria: * age from 18 to 75 years. * both sexes. * american society of anesthesiology (asa) physical status i-ii. * scheduled for total knee arthroplasty under spinal anesthesia. exclusion criteria: * patients with neurological or intellectual disability. * history of allergy to local anesthetics or dexmedetomidine . * infection at the injection site. * prolonged use of analgesic or sedative medications. * coagulation abnormalities. * pregnancy. * obesity \[body mass index (bmi) \> 30 kg/m2\].
how has glaucoma affected your quality of life?

Conditions: Glaucoma; Quality of Life

Summary: hypothesis 1: self-reported health-related quality of life decreases as vision impairment worsens in subjects with glaucoma. hypothesis 2: changes in health-related quality of life are associated with changes in clinical measures of vision and performance-based measures of visual function.

you are being asked to participate in this research study because you have glaucoma, which is the second leading cause of blindness in the world and accounts for 15% of blindness worldwide. vision loss caused by glaucoma can significantly worsen your health-related quality of life. despite the fact that glaucoma has such a big impact on a large number of people, research examining the long-term effects of glaucoma-related vision loss on one's quality of life is scarce. the purpose of this study is to look at the long-term effect of this condition on your quality of life so that we may gain valuable information about what factors influence the quality of life of people with glaucoma. to participate in this study, you will need to allow us to perform clinical tests on your eyes, to self-report your well-being and health-related quality of life, and to let us know how well you perform your daily life activities.

Eligibility criteria:
inclusion criteria: * minimum 2-year diagnosis of primary open-angle glaucoma, chronic primary angle-closure glaucoma or exfoliation glaucoma * disk damage likelihood scale stages 5 through 8 with visual field loss * age between 21 and 80 years * able to understand and speak english exclusion criteria: * unlikely to be available for annual ocular examination and reassessment across a 4-year period * neurological or musculoskeletal problems that would influence performance on activities of daily living * cognitively impaired, as assessed by a face-to-face mini-mental state examination * incisional eye surgery within the past three months * laser therapy within the previous month * any cause for visual reduction other than glaucoma * any medical condition which in the investigator's opinion would preclude the subject from providing reliable and valid data

Keywords: health related quality of life clinical measures of vision
fractional handpiece with co2 laser: fractional ablative laser treatment of vulvovaginal atrophy

Conditions: Vulvovaginal Atrophy

Summary: to assess the feasibility and efficacy of the co2 fractional handpiece in the treatment of vulvovaginal atrophy (vva) in post-menopausal women and its effect on the patient vhis(vaginal health index core). the primary endpoint is to assess the change in the vaginal dryness by means of a visual analogic scale (10 cm vas).

the purpose of this study is to evaluate the use of a co2 laser (edgetm co2 laser) with a fractional handpiece made specifically for the vagina to possibly restore the normal physiological conditions of the vagina, thus reducing the symptoms of vva. the edgetm co2 laser and general fractional handpiece is approved by the fda for ablative skin resurfacing (for example, treating fine lines and wrinkles, acne and surgical scars, skin pigmentation and discoloration, sun damage, pre-cancerous as well as benign lesions and uneven skin texture). the fractional handpiece used in this study for the treatment of vva is experimental and has not been approved by the fda for vaginal dryness associated with menopause.

Eligibility criteria:
inclusion criteria: * subjects meeting the following inclusion criteria may participate: * healthy non-smoking post menopausal women with absence of menstruation of at least 12 months * exhibiting vva symptoms * prolapse staged \< ii, according to the pelvic organ prolapse quantification (ics-pop- q) system * have not had procedures in the anatomical area through 6 months prior to treatment * understand and accept the obligation and is logistically able to present for all scheduled follow-up visits exclusion criteria: * subjects meeting any of the following criteria will be excluded from participation: * acute or recurrent urinary tract infection (uti), or genital infection (e.g. herpes candida). * prolapse staged ≥ ii, according to the pelvic organ prolapse quantification (ics-pop- q) system * any serious disease, or chronic condition, that could interfere with the study compliance * previously undergone reconstructive pelvic surgery * have used vaginal creams, moisturizers, lubricants or homeopathic preparations for at least 3 months * a history of thrombophlebitis * a history of acute infections * a history of heart failure * received or is anticipated to receive antiplatelets, anticoagulants, thrombolytics, vitamin e or anti inflammatories within 2 weeks pre treatment * any medical condition, that, in the investigator's opinion would interfere with the patient's participation in the study * taking medications that are photosensitive * a history of keloid formation
investigating the effectiveness of graded motor imagery training in children with obstetric brachial plexus injury

Conditions: Obstetric Brachial Plexus Injury

Summary: the aim of this study is to investigate the effect of graded motor imagery training on upper extremity motor function, proprioception, functional mobility, balance and quality of life in patients with obstetric brachial plexus injury in addition to conventional treatment. in this context, our aim is to identify new and potential physiotherapeutic approaches to address deficits in motor planning that have been shown to occur at the level of the central nervous system.

this study was planned as a randomized, controlled, single-blind study. the aim of this study was to investigate the effects of graded motor imagery (gmi) training, performed in addition to conventional treatment of patients with obstetric brachial plexus injury, on upper extremity motor function, proprioception, functional mobility and quality of life. in parallel to the initial assessment, a conventional physiotherapy program was created that is individualized according to the functional status and severity of the effects in the children. in the gmi program, in addition to this program, the components of gmi training are applied to sequentially activate the cortical motor networks and develop cortical organization. all assessments of the participants before and at the end of the treatment are carried out by a blind physiotherapist.

Eligibility criteria:
inclusion criteria: * obtaining family consent and the child's willingness * being between the ages of 7-18 * being diagnosed with obstetric brachial plexus injury * not having received physical therapy in the last 6 months exclusion criteria: * having a traumatic (postnatal) brachial plexus injury * having undergone surgery for complications related to brachial plexus injury within the last six months (release, tendon transfer, osteotomy, etc.) * having another neurological, neuromuscular, musculoskeletal or cardiopulmonary system disease in addition to obpi
effect of triple versus quadruple therapy for treating helicobacter pylori infection -an open label randomized controlled trial

Conditions: Dyspepsia

Summary: the goal of this this clinical trial is to assess and compare the eradication rate of triple and quadruple therapy during treating helicobacter pylori infection among patients presented with dyspepsia. it will also assess the patient reported adverse events among two groups. h pylori infection will be confirmed by clo (rut) test and stool antigen test both. standard triple therapy will be based on esomeprazole 20 mg bd, clarithromycin 500mg bd and amoxicillin 1gm bd. bismuth quadruple therapy consists of bismuth subsalicylate 300mg qds, tetracycline 500mg qds and metronidazole 400mg tds. patient will be confirmed h pylori eradication 4 weeks after completion of treatment by stool antigen test only.

this randomized controlled trial study aims to compare the eradication rates of helicobacter pylori infection between quadruple therapy and triple therapy in dyspeptic patients at dhaka medical college \& hospital. sixty-six participants, selected through purposive sampling, will be randomly allocated into two groups: 33 patients in group a (receiving triple therapy) and 33 in group b (receiving quadruple therapy). after pre-procedural preparation, a clo test will be conducted during endoscopy and a stool antigen test to detect h. pylori. participants will undergo treatment for 14 days, followed by follow-up testing 4 weeks later to evaluate eradication. ethical approval will be obtained, and confidentiality will be maintained.

Eligibility criteria:
inclusion criteria: 1. all dyspeptic patients aged ≥18 years. 2. patients with positive clo test and stool antigen test both. 3. patients who will provide informed written consent and agree to follow-up at 4 weeks post-treatment. - exclusion criteria: 1. patients who have received prior h. pylori eradication therapy. 2. ingestion of antibiotics or proton pump inhibitor within the prior 4 weeks. 3. patients with known allergies or intolerance to any of the study medications. 4. patients with alarm symptoms (e.g., unexplained weight loss, persistent vomiting, gastrointestinal bleeding, dysphagia). 5. patients with a history of gastric surgery. 6. pregnant or lactating women. -
utrecht coronary biobank (ucorbio)

Conditions: Coronary Artery Disease

Summary: ucorbio enrolls patients who undergo coronary angiography (for any indication). the investigators draw blood at the moment of insertion of the procedural arterial catheter. at the moment of inclusion indication, procedural details, risk factor status, medication use and quality of life (rand-36 and euroqol) is assessed. patients are then followed-up for the occurrence of major adverse cardiovascular events for 5 years. during the follow-up period patients receive a questionnaire every year to check for hospital admissions. the questionnaires at two and five years of follow-up are enriched with quality of life questionnaires (rand-36 and euroqol).


Eligibility criteria:
inclusion criteria: * coronary angiography exclusion criteria: * age \< 18 years.
egfr-tki with/without chemotherapy in nsclc patients with both egfr mutation and bim deletion polymorphism

Conditions: Nonsmall Cell Lung Cancer; EGFR Gene Mutation

Summary: bim deletion polymorphism might be associated with a poor clinical response to egfr-tkis in patients who had nsclc with egfr mutations. in the study, the investigators want to use egfr-tki with/without chemotherapy as first line treatment in stage iiib/iv nsclc patients with both egfr mutation and bim deletion polymorphism.

bim deletion polymorphism was a poor clinical response marker to egfr-tkis in nsclc patients who had egfr mutations. in the study, the investigators want to use egfr-tki with chemotherapy as 1 st treatment in stage iiib/iv nsclc patients with both egfr mutation and bim deletion polymorphism.

Eligibility criteria:
inclusion criteria: 1. signed informed consent 2. histologically documented, unresectable, inoperable, locally advanced, recurrent or metastatic stage iv non-small cell lung cancer (nsclc) 3. must have measurable or non-measurable disease 4. must be able to comply with study and follow-up procedures exclusion criteria: 1. small cell, carcinoid, or mixed small cell lung cancer 2. malignancies within 3 years except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer 3. symptomatic or untreated brain metastases prior systemic chemotherapy for nsclc 4. unstable systemic disease, including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, or myocardial infarction within 6 months prior to day 1, or serious cardiac arrhythmia requiring medication 5. history of other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the patient at high risk from treatment complications 6. gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous (iv) alimentation, or prior surgical procedures affecting absorption 7. pregnancy or lactation